This paper introduces an interpretable pipeline that integrates mobility and social media data to analyze human behavior during crises. The framework was evaluated through two case studies, including a longitudinal analysis of UAE COVID-19 behavior from March 2020 to December 2021. The pipeline aligns heterogeneous daily signals, transforms them into binary behavioral states, applies Formal Concept Analysis (FCA) to extract co-occurrence structures, and mines association rules. Results demonstrate clear cross-domain behavioral structures in crises, yielding both scientifically credible and policy-actionable intelligence. Why it matters: This work provides a novel methodological approach for developing actionable crisis management strategies by fusing multimodal data, directly applicable to public health and emergency response in the UAE and the broader region.
KAUST and King Faisal Specialist Hospital and Research Centre (KFSH&RC) are collaborating to develop bioelectronic sensors for rapid pathogen detection. These sensors aim to provide cheap and accurate results, potentially replacing conventional lab tests. A COVID-19 saliva test developed by KAUST researchers showed comparable sensitivity to PCR tests with a 15-minute turnaround. Why it matters: This partnership accelerates the development of novel diagnostic tools, which could improve healthcare accessibility in remote areas and low-income countries within the region.
KAUST researchers have developed a CRISPR-Cas system using a heat-stable Cas13 protein (TccCas13a) from Thermoclostridium caenicola, compatible with RT-LAMP for rapid viral detection. The new assay, named OPTIMA-dx, enhances the specificity of RT-LAMP tests by reducing false positives in SARS-CoV-2 detection. The team, led by Dr. Magdy Mahfouz and doctoral student Ahmed Mahas, is transitioning the product to a startup phase for commercialization. Why it matters: This innovation could significantly improve point-of-care diagnostics for COVID-19 and other infections by providing a more accurate and easier-to-use testing method.
A KAUST-led team developed NIRVANA, a portable, briefcase-sized device for rapid detection and sequencing of SARS-CoV-2, influenza, and other viruses. The test utilizes isothermal recombinase amplification (RPA) and was validated on clinical samples and wastewater. NIRVANA can differentiate SARS-CoV-2 strains and doesn't require expensive infrastructure. Why it matters: This innovation enables rapid, decentralized virus detection and surveillance, crucial for pandemic response and monitoring new variants across the region.
A retrospective study in Abu Dhabi, UAE, developed a machine learning-based prognostic system to predict the risk of seven complications in COVID-19 patients using data from 3,352 patient encounters. The system, trained on data from the first 24 hours of admission, achieved high accuracy (AUROC > 0.80) in predicting complications like AKI, ARDS, and elevated biomarkers in geographically split test sets. The models primarily used gradient boosting and logistic regression.
A KAUST team led by Xin Gao developed an AI model for COVID-19 detection from CT scans, addressing limitations of existing methods. The model incorporates a novel embedding strategy, a CT scan simulator, and a 2.5D deep-learning algorithm. Tested at King Faisal Specialist Hospital, the model demonstrated high accuracy in detecting COVID-19 cases. Why it matters: This research provides a valuable tool for rapid and accurate COVID-19 diagnosis in the region, especially in early-stage infections, improving healthcare outcomes.
MBZUAI Professor Agathe Guilloux developed the SigLasso model to forecast hospitalizations using real-time data from Google and Météo France during the COVID-19 pandemic. The model integrates mobility data and weather patterns to predict hospitalization rates 10-14 days in advance. SigLasso outperformed industry standards like GRU and Neural CDE in reducing reconstruction error. Why it matters: This research demonstrates the potential of AI to improve healthcare resource allocation and crisis management by accurately predicting patient flow using readily available data.
SEHA and MBZUAI have signed an MoU to integrate AI into medical care and enhance clinical expertise. They will collaborate on AI-driven solutions for quantifying COVID-19 infection severity and study its long-term impact on UAE residents. The partnership will also focus on diagnosis and treatment methods for acute kidney injury, coronary artery disease, fetal health, and AI-driven point of care ultrasound. Why it matters: This collaboration between a major healthcare provider and an AI university in the UAE could lead to advancements in AI-driven healthcare solutions and improve patient outcomes.